Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion

Fineline Cube Dec 12, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...

Company Deals

Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...

Company Drug

Sisram Medical’s Profhilo Accepted for Review by China’s NMPA

Fineline Cube Dec 12, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196),...

Company Drug

Staidson Pharmaceutical Initiates Clinical Study for ARDS Treatment STSA-1002

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing...

Company Medical Device

Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System

Fineline Cube Dec 12, 2023

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Drug

Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...

Company Medical Device

Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval

Fineline Cube Dec 12, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...

Company Drug

Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA

Fineline Cube Dec 12, 2023

Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...

Company Deals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

Fineline Cube Dec 12, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...

Company Deals

Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine

Fineline Cube Dec 12, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...

Company Deals

Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China

Fineline Cube Dec 12, 2023

Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...

Policy / Regulatory

CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20

Fineline Cube Dec 11, 2023

The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...

Company Drug

Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC

Fineline Cube Dec 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...

Company Deals

Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform

Fineline Cube Dec 11, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies

Fineline Cube Dec 11, 2023

Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...

Company Deals

Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging

Fineline Cube Dec 11, 2023

Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...

Company Drug

MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints

Fineline Cube Dec 11, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...

Company Drug

Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer

Fineline Cube Dec 11, 2023

Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...

Company

Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District

Fineline Cube Dec 11, 2023

Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...

Company Drug

Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis

Fineline Cube Dec 8, 2023

Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a...

Posts pagination

1 … 378 379 380 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.